Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics, Inc. (VYGR)
Last voyager therapeutics, inc. earnings: 3/3 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.voyagertherapeutics.com
Company Research
Source: GlobeNewswire
LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE: NVS) has agreed to license a novel capsid generated from Voyager’s TRACER™ capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally announced in March 2022. “Novartis is a global leader in gene therapy, and we view their continued selection of our IV-delivered, blood-brain barrier-penetrant capsids as strong validation of our TRACER capsid discovery platform,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “We are proud of the continued success of the relationship between Voyager and Novartis, which now includes five gene therapy programs: Huntington’s disease, spinal muscular atrophy, and
Show less
Read more
Impact Snapshot
Event Time:
VYGR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYGR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYGR alerts
High impacting Voyager Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VYGR
News
- Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s DiseaseGlobeNewswire
- Voyager Therapeutics, Inc. (NASDAQ: VYGR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $14.00 price target on the stock.MarketBeat
- Voyager Therapeutics, Inc. (NASDAQ: VYGR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.MarketBeat
VYGR
Earnings
- 11/12/24 - Beat
VYGR
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- VYGR's page on the SEC website